The COVID-19 impact on severe uncontrolled asthma costs and biologic use

Najm S Khan1, Elizabeth Rubin2, Bernard McKenna3

  • 1From the Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey.

PubMed

Insights

The COVID-19 pandemic reduced healthcare costs for severe uncontrolled asthma (SUA) patients, but increased prescription expenses. Biologic therapy use also significantly declined during this period.

Area of Science:

  • Pulmonary Medicine
  • Health Economics
  • Epidemiology

Background:

  • Severe uncontrolled asthma (SUA) poses a significant economic burden and often necessitates biologic therapy.
  • The impact of the COVID-19 pandemic on asthma-related costs and biologic utilization remains unevaluated.

Purpose of the Study:

  • To investigate the hypothesis that costs and biologic use for severe uncontrolled asthma decreased during the COVID-19 pandemic.

Main Methods:

  • Analysis of medical costs and biologic use in severe uncontrolled asthma patients from January 2017 to December 2021.
  • Utilized claims data from a large managed care organization and electronic health records from Robert Wood Johnson Barnabas Health.
  • Data stratified by provider specialty (primary care physicians and specialists).

Main Results:

  • Total healthcare costs for severe uncontrolled asthma patients decreased during the pandemic across all care groups (34%-45% reduction).
  • Inpatient and outpatient costs declined, while prescription costs increased.
  • Biologic use, which was increasing pre-pandemic, saw a twofold decrease and remained low.

Conclusions:

  • The COVID-19 pandemic led to decreased inpatient and outpatient costs but increased prescription costs for severe uncontrolled asthma patients.
  • Biologic utilization among severe uncontrolled asthma patients significantly decreased during the pandemic and stayed reduced.

Related Concept Videos

Asthma-III: Symptoms and Complications01:24

Asthma-III: Symptoms and Complications

Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
2.5K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
442
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
298
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.7K
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
244